Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
出版年份 2017 全文链接
标题
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
作者
关键词
-
出版物
JNCI-Journal of the National Cancer Institute
Volume 109, Issue 9, Pages -
出版商
Oxford University Press (OUP)
发表日期
2017-01-30
DOI
10.1093/jnci/djx014
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A gp130–Src–YAP module links inflammation to epithelial regeneration
- (2015) Koji Taniguchi et al. NATURE
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
- (2015) Luping Lin et al. NATURE GENETICS
- EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function
- (2015) Janyaporn Phuchareon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
- (2015) Collin M. Blakely et al. Cell Reports
- Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
- (2014) Ho-June Lee et al. CANCER CELL
- TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF- B and Regresses Mutant EGFR-Associated Human Non-Small Cell Lung Cancers
- (2014) J. Nan et al. MOLECULAR CANCER THERAPEUTICS
- Genetics and biomarkers in personalisation of lung cancer treatment
- (2013) Rafael Rosell et al. LANCET
- β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis
- (2012) Joseph Rosenbluh et al. CELL
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents
- (2011) W. Fan et al. CANCER RESEARCH
- Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
- (2011) R. Rosell et al. CLINICAL CANCER RESEARCH
- FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
- (2011) Trever G. Bivona et al. NATURE
- Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor–Activating Mutations
- (2010) Matthew J. Lazzara et al. CANCER RESEARCH
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Enhanced Sensitivity of Pancreatic Cancer Cells to Concurrent Inhibition of Aberrant Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor or Src
- (2010) S. Jaganathan et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
- (2009) Rafael Rosell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Roles of unphosphorylated STATs in signaling
- (2008) Jinbo Yang et al. CELL RESEARCH
- Signaling networks assembled by oncogenic EGFR and c-Met
- (2008) A. Guo et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now